Table I.
Association between NNMT expression and the clinicopathological parameters of PCa.
| NNMT expression, n (%) | ||||
|---|---|---|---|---|
|
|
||||
| Characteristics | Patients, n | High | Low | P-value |
| Age, years | 0.219 | |||
| <69 | 61 | 40 (65.6) | 21 (34.4) | |
| ≥69 | 59 | 33 (55.9) | 26 (44.1) | |
| PSA, ng/ml | 0.808 | |||
| ≤10 | 21 | 14 (66.7) | 7 (33.3) | |
| >10 | 99 | 59 (59.6) | 40 (40.4) | |
| Distant metastasis (pM1) | 0.452 | |||
| Yes | 56 | 32 (57.1) | 24 (42.9) | |
| No | 64 | 41 (64.1) | 23 (35.9) | |
| Lymph metastasis (pN1) | 0.385 | |||
| Yes | 28 | 19 (67.9) | 9 (32.1) | |
| No | 92 | 54 (58.7) | 38 (41.3) | |
| pT-status | 0.442 | |||
| pT1/2 | 25 | 17 (68.0) | 8 (32.0) | |
| pT3/4 | 95 | 56 (58.9) | 39 (41.1) | |
| Gleason score | <0.001a | |||
| 5–6 | 31 | 28 (90.3) | 3 (9.7) | |
| 7 | 21 | 15 (71.4) | 6 (28.6) | |
| 8–10 | 68 | 30 (44.1) | 38 (55.9) | |
a
P<0.05.
NNMT, Nicotinamide N-methyltransferase; PCa, prostate cancer; PSA, prostate-specific antigen.